Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

European Hematology Association Congress (EHA 2025)

Jun 12, 2025 • 5:00 pm - 6:15 pm CEST